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Abstract
Introduction. The Vipera berus (common viper) is the only species of venomous snake found in Poland. The aim of this 
study was to determine to what extent coagulopathy has occurred as a post-bite complication.  
Materials and method. The medical records of 138 adult patients in the Sucha Beskidzka hospital with the diagnosis of 
snake bite between 2001–2014 were retrospectively analyzed. Demographic, clinical and laboratory data were collected. 
Antivenom was given to all patients, except one, with snake bites, but laboratory test were taken prior to administration 
of antivenom. Obtained results were compared to those of the control group, composed of 176 adults hospitalized in the 
same period for an elective laparoscopic cholecystectomy.  
Results. The mean platelet count in the study group was 239.94×109/L (SD=56.56) and 248.77×109/L (SD=57.82) in the 
control group. In 98% of the study group and 100% of the control group the platelet value (PLT) fell within laboratory 
norms (130 to 420×109/L), 2 patients after snake bites had a PLT lower than normal, and thrombocytosis was not observed 
in either group. A reference range of 0.85–1.3 INR below normal was found in 2 patients in the study group and 15 from 
the control group, while values above the normal range were found in 8 patients (6.7%) from the snake bite group and no 
patients from the control group. In the study group, the INR ranged from 0.78–1.43 with a mean of 1.046 (SD=0.14), while 
in the control group the range was from 0.79–1.28, with a mean of 0.95 (SD=0.08). There was a significant difference in INR 
between the study and control groups (p<0.0001).   
Conclusions. The bite from V. berus does not result in severe thrombocytopenia, with only a moderate increase in INR 
values observed in about 7% of patients.
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INTRODUCTION
Venomous snakes compose about 20% of all snake species, 
and are most commonly found in regions such as Australia 
or Asia. The two most common snake families responsible 
for the highest burden of bites are the Viperidae and 
Elapidae families. Typically, elapidous snake bites lead to 
neurotoxicity [1] and viperous bites to coagulopathy, which 
is one of the most common systemic complications and 
cause of death amongst venomous animals worldwide [2]. 
The only venomous snake found in Poland is the Vipera 
berus L.1758, commonly known as the viper snake [3, 4]. 
According to recent information from the Polish Ministry 
of the Environment there is no data about the size of Vipera 
berus population in Poland [5]. On the other hand, in some 
habitats up to 59 snakes per hectare have been recorded [6].
To describe the various types of blood clotting disorders 
arising from bites, the term “venom-induced consumption 
coagulopathy” (VICC) has been introduced. VICC occurs 
following bites from a variety of snakes, including, but not 
limited to, Viperid and Elapid snakes. Snake venom contains 
procoagulant toxins, such as factor V, X, and prothrombin 
activators, fibrinogenases and thrombin-like enzymes (TLE). 
Some of these are more potent than others, and the severity 
and duration of symptoms varies between toxins. Factor 
activators lead to factor depletion and deficiencies, while TLE’s 
and fibrinogenases cleave fibrinogen without forming fibrin, 
causing a low to undetectable blood fibrinogen concentration. 
Diagnosis of VICC is performed by measuring clotting times, 
most commonly prothrombin (PT), partial thromboplastin 
time (PTT), and the international normalized ratio (INR) 
[7, 8]. VICC describes coagulopathies; however, it is not 
synonymous with disseminated intravascular coagulation 
(DIC). Hallmark features of DIC, such as systemic 
microthrombi and end organ failure, are not present is VICC 
[2]. Viperid and elapid snake bites are also observed to elicit 
complications consistent with thrombotic microangiopathy, 
with development of acute renal failure, thrombocytopenia, 
and microangiopathic haemolytic anaemia [7]. Mortality 
post-VICC is dependent on many factors, including platelet 
count, function, trauma and presence of vascular injury. 
Vessel damage may lead to haemorrhages through the release 
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of tissue factor. Bleeding severity has a wide range, from local 
bleeding to life- threatening intracranial or multi-organ 
haemorrhaging. [8].
VICC diagnosis is usually a combination of patient history 
which includes the snake bite and blood test results indicating 
factor consumption coagulopathy. Blood test findings can 
include abnormal INR or PT, low fibrinogen or elevated 
D-Dimer levels. Fibrinogen is the most commonly consumed 
clotting factor in snake bites [8]. The above observations 
apply mainly to tropical snakes, including the viperous 
species. However, a recent study performed by Polish and 
Slovak researchers demonstrated that the venom of Vipera 
berus contains a full spectrum of haemotoxins [9]. These 
are thrombin like enzymes, serine proteases, activators of 
protein C, phospjholipases A2, C-type lectin like proteins 
and snake venom metalloproteinases.
In Central European countries, venomous snakes are 
represented only by V.berus. In the literature, coagulopathy 
is listed as one of the effects of V.berus; however, there is 
little data pertaining to the frequency of this complication 
in clinical practice.
The present study reports data from the hospital in Sucha 
Beskidzka, a town located in the north-western part of 
Carpathian Mountains (49°  44′  25″  N,  19°  35′  19″  E) in 
Poland, a region where the V.berus population is large. 
V.berus is the most common among all of venomous snakes 
found in Europe. This species can be found in a variety of 
habitats from grassy fields to rocky slopes, and on farms and 
cultivated lands [6].
OBJECTIVE
The aim of this study was to determine to what extent 
coagulopathy has occurred as a complication of V.berus bites 
among the patients from the hospital in Sucha Beskidzka, 
Poland.
MATERIALS AND METHOD
This was a retrospective cohort study performed between 
2001–2014 among 138 adult patients with the diagnosis of 
snake bite. The number of cases per year ranged from 4–15, 
with the average of 9.85. In the same period, 42 children were 
admitted after a V.berus bite; however, children were excluded 
from the study because of the lack of an adequate control 
group. The events occurred between April and September, 
with the highest incidence in June and July. Data about 
the patients were collected retrospectively from medical 
documentation. It included information on demographics – 
age, gender (Tab. 1), history, month of hospitalization, length 
of hospital stay, site of bite, local and systemic symptoms of 
envenomation, intensity of symptoms, and blood test results.
The intensity of symptoms was rated on a 4-degree scale: 
grade 0 (G0) – ‘dry’ bite without signs of envenomation, with 
the presence of teeth marks; grade 1 (G1) – mild poisoning, 
with limited local symptoms, reaching its peak after 24–48 
hours; grade 2 (G2) – average poisoning with regional oedema 
on affected limb and mild systemic symptoms (mild nausea, 
abdominal pain, diarrhea, slight changes in arterial blood 
pressure, tachycardia, hypotonia); grade 3 (G3) – severe 
poisoning with diffuse oedema spreading to the abdomen, 
life-threatening systemic symptoms (significant or prolonged 
hypotonia, haemorrhagic shock) [10]. Blood tests were carried 
out within 1–4 hours after patient admission to hospital, 
but prior to the administration of antivenom. In the control 
group, blood tests were carried out on the day of admission. 
For the assessment of blood clotting, the International 
Normalized Ratio (INR) and platelet count (PLT) were 
measured. The local laboratory norm for INR is between 
0.85–1.3, while the laboratory norm for PLT is between 
130–420×109/L. None of the patients used anticoagulant 
medications prior to admission. All the patients (except one 
who refused) with snake bites received antivenom serum 
(Immunoserum contra venena viperarum europaearum, 
BIOMED, Warsaw, Poland), at the dose of 500 antitoxic U im. 
A group of 138 patients (70 women and 68 men) was qualified 
for the study, with ages ranging from 18 to 90 years; mean 
age – 49. In this group, platelet counts at admission were 
measured in 127 patients, and INR at admission in 119. Both 
parameters were measured in 118 patients, platelet count 
only in 9 patients and INR only in one patient. In 10 patients, 
only clinical assessment without blood tests on admission 
was performed. This occurred because blood tests were at 
the discretion of the consulting physician. Routine physical 
examinations were performed in all 138 patients, including 
assessment of the signs of impaired coagulation (bleeding, 
bruises, ecchymoses, thrombosis, etc.). Obtained results were 
compared with a control group of adults admitted for an 
elective laparoscopic cholecystectomy. These patients were 
from the same geographic region as the study group, and 
their hospitalizations occurred in the same months as those 
of the viper bite patients. The control group was composed 
of 176 patients (90 women and 86 men); mean age – 52 years. 
Statistical analysis on PLT and INR mean values between the 
study and the control groups was performed (comparison of 
means statistics), and significance accepted at p<0.05.
RESULTS
In 70 cases, snake bites affected the upper extremity, in 67 
the lower extremity and in one case, the trunk. Among all 
patients, 72 presented with Grade 2 symptoms (52%), 50 with 
G1 (36%), 11 with G0 (8%), and only 5 with G3 (4%) severity 
of symptoms (Tab.2).
No clinical symptoms of coagulopathy were observed. 
Local symptoms of haematoma were found in 59 patients 
(43%), while oedema was observed in 123 cases (89%). No 
Table 2. Severity of poisoning in study group
Severity of poisoning in study group G0 G1 G2 G3
No. of patients 11 50 72 5
% of patients (%) 8 36.2 52.2 3.6
Table 1. Demography of patients
Age groups (years) <18 18–65 >65
Gender
Males 24 61 10
Females 18 51 16
Total 42 112 26
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thromboembolic complications were recorded. In 17 patients, 
low molecular weight heparin (LMWH) was administered 
due to marked oedema of the lower extremity. No side-
effects of antivenom administration were observed. In the 
10 patients who had no blood tests within 1–4 hours after 
admission to the hospital, 2 were assessed as G0, 3 as G1, 
and 4 as G2, 1 as G3.
Table 3 shows the results of measured and calculated 
parameters in the study and control groups.
The mean platelet count in the study group was 239.94×109/L 
(SD = 56.56) which was lower than that of the control group 
248.77×109/L (SD=57.82). This difference did not reach 
statistical significance. In 98% of the study group and 100% 
of the control group the platelet value fell within laboratory 
norms. Only 2 patients after snake bites had a platelet value 
lower than normal. Thrombocytosis was not observed in 
either group (Fig.1a).
For further analysis, the study group was divided into 
2 subgroups according to the intensity of symptoms: 
G0+G1 (n=56) and G2+G3 (n=71). The mean platelet count 
were 249×109/L (SD=55.39) and 232.8×109/L (SD=56.84), 
respectively. There was no statistically significant difference 
between the G0+G1 and G2+G3 subgroups in PLT count 
distribution (Fig. 1b).
The distribution of INR was as follows: INR below 
normal (N:0.85–1.3) was found in 2 patients in the study 
group and 15 patients from the control group, while values 
above the  normal range were found in 8 patients (6.7%) 
from the snake bite group and no patients from the control 
group. In the study group, the INR ranged from 0.78–1.43, 
and  in  the  control group, the range was from 0.79–1.28. 
(Fig. 2a).
Mean INR in the study group was 1.046 (SD=0.14), 
which was higher than the mean in the control group – 0.95 
(SD=0.08). Statistical analysis showed a significant difference 
between INR in study and control groups (p<0.0001; 95% CI 
-0.1209 to -0.0711).
Analysis in the G0+G1 and G2+G3 subgroups showed 
that the mean INR was 1.06 (SD=0.13) and 1.03 (SD=0.15), 
respectively. There was no statistical difference between 
subgroups in mean count, nor in the distribution of results 
(Fig. 2b).
DISCUSSION
This study was carried out in a single centre, a regional hospital 
in southern Poland located close to the known habitats of 
the V. berus. It analyses one of the largest data collections 
from a single centre, whereas other larger studies have been 
rather nationwide studies [11, 12, 13]. The data were collected 
during 14 years and based upon clinical records. No extensive 
Table 3. Results in study and control group
Study group Control group
Parameter mean SD median min max IQR mean SD median min max IQR p-value
PLT 239.9 56.56 237 113 396 85 248.7 57.82 242.2 133.2 402.1 68 0.2844
INR 1.046 0.1368 1.030 0.78 1.430 0.19 0.95 0.08 0.95 0.79 1.280 0.11 <0.0001
Figure 1a and 1b. Comparison of platelet count between study and control groups [1a] and Distribution of platelet count in G0+G1 and G2+G3 subgroups [1b]
Figure 2a and 2b. Comparison of INR values between study and control groups [2a] and Distribution of INR values in G0+G1 and G2+G3 subgroups [2b]
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laboratory tests were used. The majority of patients had their 
INR and PLT values measured on admission. There are some 
literature data which states that in patients after a bite by the 
common viper, measurements of fibrinogen levels may be 
useful [7]. However, this parameter was not assessed in the 
current study, since none of the patients had clinical signs 
of VICC and there were no indications for detailed blood 
clotting tests. Blood clotting disorders are reported as one of 
the consequences of V. berus bite; however, they are probably 
not common [8, 10]. No report was found in the literature 
which focused on this subject. The presented group is large 
enough to detect adverse effects which occur in less than 5 
– 10% of patients. There are multiple factors in the venom of 
the V. berus which may interfere with the coagulation system. 
The effects of phospholipase A2 through the activation of 
the inflammatory cascade may impair platelet function, and 
probably lead to platelet lysis. Thrombocytopenia has been 
reported as an important consequence and prognostic factor 
in patients after a bite from exotic snakes from India [14]. The 
case of a patient with severe thrombocytopenia after a bite 
from the Vipera ammodytes ammodytes in Bulgaria was also 
reported [15]. In the presented group of 127 patients with PLT 
count measured, only 2 patients were below normal count. 
However, in both cases the PLT count was above 100x109/L. 
In the study group, PLT count did not differ significantly from 
the control group. There was also no difference between PLT 
count in patients with minimal symptoms of envenomation 
(G0+G1) and those with more intense symptoms (G2+G3). 
This may suggest that the venom of V. berus does not lead to 
severe thrombocytopenia. In a different study from Poland, 
only one case of mild thrombocytopenia has been reported 
[16]. Another Polish study reported thrombocytopenia below 
50x109/L in 6 of 26 patients, which is contrary to findings in 
the presented study [17].
Analysis of INR results in 119 patients revealed a few 
cases with values slightly different from the normal range: 
INR was lower in 2 patients, while in 8 patients it was higher 
than normal. The differences in INR values between study 
and control groups were significant; however, there was no 
association of INR with intensity of local symptoms. The 
venom of V. berus may influence INR through altered activity 
of coagulation factor V [10, 15]. The effects may vary from 
hypercoagulation to hypocoagulation depending on the 
amount of venom [1, 10]. The presented results, however, do 
not support this observation. In a group of 15 patients from 
north-eastern Poland, INR was increased in only one case, 
which is in line with this study [16]. A nationwide French 
study [12] also did not reported serious hypocoagulation in 
patients after a V. berus bite. A case of pulmonary embolism 
in one V. berus bite patient has been reported by other French 
authors [18]. Such complications were not observed in either 
the current study nor the large study performed in France 
[12]. In a group of 17 patients from the current study, LMWH 
was administered as prophylaxis in patients with marked 
oedema of the lower extremity. This indication has also been 
reported by others [12, 17].
All except one snake bite patient received antivenom 
serum, regardless of the intensity of their symptoms. 
This may be assessed as an over-treatment; however, the 
administration of serum could not influence the results of 
initial blood tests because the blood tests were performed 
prior to administration of the antivenom, therefore the 
treatment could not influence the blood test results.
Antivenom binds the toxins and can potentially block 
the active site of a toxin. Additionally, the complexes 
(antivenom toxins) can be eliminated from circulation. On 
the other hand, irreversible toxic effects cannot be reversed 
by antivenom binding to toxins after damage such as clotting 
factor deficiencies has occurred [19]. The antivenom may 
be effective if administered early, before the impairment of 
clotting factors occurrs [20].
In the presented study, antivenom was administered early 
to the patients due to the proximity of the hospital to the place 
of the snake bite incidents. However, there was verified data 
available about the time between the bite and antivenom 
administration. Although this is the weakness of the study, 
in a retrospective study the authors were unable to obtain 
this information and it is therefore impossible to prove with 
the obtained results whether or not the administration of the 
antivenom had a beneficial effect.
This study demonstrates that the bite from V. berus does 
not result in severe thrombocytopenia, with only a moderate 
increase in INR values observed in about 7% of patients. 
Therefore, extensive blood clotting tests are probably justified 
only in severely intoxicated patients or in patients with a 
specific medical history.
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